Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3Neoplasms 2Plasmacytoma 1Pathologic Complete Response 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Large Granular Lymphocytic 1Hepatic Insufficiency 1Hematologic Neoplasms 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 3ruxolitinib 2fludarabine phosphate 2fludarabine 2Methotrexate 2thymoglobulin 1siltuximab 1duvelisib 1cc-486 1calaspargase pegol 1blinatumomab 1Whole-Body Irradiation 1Valganciclovir 1Transplantation 1Thiotepa 1Therapeutics 1Thalidomide 1Tacrolimus 1Radiotherapy 1Prednisone 1Positron-Emission Tomography 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Mesna 1Melphalan 1Interleukin-6 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Ganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Large Granular Lymphocytic × cc-486 × 1 year × Clear all
NCT05141682 2026-03-03

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Active not recruiting
11 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡